title: Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria.
abstract: We have used the ability of opsonized bacteria to stimulate luminol-enhanced chemiluminescence (CL) of human polymorphonuclear leukocytes (PMN) to examine the opsonic capabilities of commercially available human intravenous immunoglobulin (i.v.Ig) preparations. The method was tested against 14 strains of drug-resistant gram-positive bacteria (including methicillin-resistant Staphylococcus aureus, hetero-vancomycin-resistant S. aureus, vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae), and 23 strains of gram-negative bacteria (including extended-spectrum beta-lactamase-producing bacteria, metallo-beta-lactamase-producing bacteria, beta-lactamase-negative ampicillin-resistant Haemophilus influenzae). An Fc-intact i.v.Ig preparation treated with polyethylene glycol (PEG) was evaluated for opsonization effectiveness against these bacteria in vitro. The opsonization of these organisms was enhanced by an Fc-intact i.v.Ig, and the opsonic activity was dose dependent. A pepsin-treated i.v.Ig preparation exhibited poor opsonic activity for all bacteria tested. These results suggest that Fc-intact i.v.Ig, which augments opsonic activity against various drug-resistant bacteria, will be a useful addition to the treatment of severe bacterial infections in immunocompromised patients with impaired serum opsonic capacity.
authors.affiliation: Department of Microbiology & Immunology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. onoy@med.teikyo-u.ac.jp
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ono
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ito
authors.forename: Takeshi
authors.initials: T
authors.lastname: Watanabe
authors.forename: Osamu
authors.initials: O
authors.lastname: Koshio
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tansho
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Ikeda
authors.forename: Sayoko
authors.initials: S
authors.lastname: Kawakami
authors.forename: Yukihisa
authors.initials: Y
authors.lastname: Miyazawa
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000276:immunology*; D006094:Gram-Positive Bacteria / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000494:pharmacology; D008163:Luminescent Measurements; D009504:Neutrophils / Q000276:immunology*; D009895:Opsonin Proteins / Q000276:immunology*; D011092:Polyethylene Glycols; D011961:Receptors, Fc
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D009895:Opsonin Proteins; D011961:Receptors, Fc; D011092:Polyethylene Glycols